823 related articles for article (PubMed ID: 17387156)
41. Over-treatment of carbapenemase-producing Enterobacteriaceae.
Rihani DS; Wallace MR; Sieger BE; Waite RA; Fox M; Brown SA; Deryke CA
Scand J Infect Dis; 2012 May; 44(5):325-9. PubMed ID: 22200121
[TBL] [Abstract][Full Text] [Related]
42. Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia. Risk factors and outcome in the eastern region of Saudi Arabia.
Memon JI; Rehmani RS; Ahmed MU; Elgendy AM; Nizami IY
Saudi Med J; 2009 Jun; 30(6):803-8. PubMed ID: 19526164
[TBL] [Abstract][Full Text] [Related]
43. Risk factors for and mortality of extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli nosocomial bloodstream infections.
Superti SV; Augusti G; Zavascki AP
Rev Inst Med Trop Sao Paulo; 2009; 51(4):211-6. PubMed ID: 19739001
[TBL] [Abstract][Full Text] [Related]
44. Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy.
Kang CI; Wi YM; Ko KS; Chung DR; Peck KR; Lee NY; Song JH
Scand J Infect Dis; 2013 Jul; 45(7):519-25. PubMed ID: 23509913
[TBL] [Abstract][Full Text] [Related]
45. Burden of bloodstream infection caused by extended-spectrum β-lactamase-producing enterobacteriaceae determined using multistate modeling at a Swiss University Hospital and a nationwide predictive model.
Stewardson A; Fankhauser C; De Angelis G; Rohner P; Safran E; Schrenzel J; Pittet D; Harbarth S
Infect Control Hosp Epidemiol; 2013 Feb; 34(2):133-43. PubMed ID: 23295559
[TBL] [Abstract][Full Text] [Related]
46. [Bacteremia caused by Escherichia coli and Klebsiella pneumoniae producing extended-spectrum betalactamases: mortality and readmission-related factors].
Perianes-Díaz ME; Novo-Veleiro I; Solís-Díaz K; Prolo-Acosta A; García-García I; Alonso-Claudio G
Med Clin (Barc); 2014 May; 142(9):381-6. PubMed ID: 23735867
[TBL] [Abstract][Full Text] [Related]
47. [Bacteraemia due to extended-spectrum beta-lactamases (ESBL) and other beta-lactamases (ampC and carbapenemase) producing Enterobacteriaceae: association with health-care and cancer].
García-Gómez M; Guío L; Hernández JL; Vilar B; Pijoán JI; Montejo JM
Rev Esp Quimioter; 2015 Oct; 28(5):256-62. PubMed ID: 26437756
[TBL] [Abstract][Full Text] [Related]
48. Emergence of extended-spectrum β-lactamase-producing escherichia coli as a cause of community-onset bacteremia in South Korea: risk factors and clinical outcomes.
Park SH; Choi SM; Lee DG; Kim J; Choi JH; Kim SH; Kwon JC; Yoo JH
Microb Drug Resist; 2011 Dec; 17(4):537-44. PubMed ID: 21875342
[TBL] [Abstract][Full Text] [Related]
49. Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Oh MD; Kim EC; Choe KW
Clin Infect Dis; 2004 Sep; 39(6):812-8. PubMed ID: 15472813
[TBL] [Abstract][Full Text] [Related]
50. Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy.
Tumbarello M; Sali M; Trecarichi EM; Leone F; Rossi M; Fiori B; De Pascale G; D'Inzeo T; Sanguinetti M; Fadda G; Cauda R; Spanu T
Antimicrob Agents Chemother; 2008 Sep; 52(9):3244-52. PubMed ID: 18591273
[TBL] [Abstract][Full Text] [Related]
51. Extended-spectrum β-lactamase (ESBL) in Danish clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence, β-lactamase distribution, phylogroups, and co-resistance.
Hansen DS; Schumacher H; Hansen F; Stegger M; Hertz FB; Schønning K; Justesen US; Frimodt-Møller N;
Scand J Infect Dis; 2012 Mar; 44(3):174-81. PubMed ID: 22364227
[TBL] [Abstract][Full Text] [Related]
52. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae.
Palacios-Baena ZR; Gutiérrez-Gutiérrez B; De Cueto M; Viale P; Venditti M; Hernández-Torres A; Oliver A; Martínez-Martínez L; Calbo E; Pintado V; Gasch O; Almirante B; Antonio Lepe J; Pitout J; Akova M; Peña-Miralles C; Schwaber MJ; Tumbarello M; Tacconelli E; Origüen J; Prim N; Bou G; Giamarellou H; Bermejo J; Hamprecht A; Pérez F; Almela M; Lowman W; Hsueh PR; Navarro-San Francisco C; Torre-Cisneros J; Carmeli Y; Bonomo RA; Paterson DL; Pascual Á; Rodríguez-Baño J;
J Antimicrob Chemother; 2017 Mar; 72(3):906-913. PubMed ID: 28062685
[TBL] [Abstract][Full Text] [Related]
53. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.
Zaoutis TE; Goyal M; Chu JH; Coffin SE; Bell LM; Nachamkin I; McGowan KL; Bilker WB; Lautenbach E
Pediatrics; 2005 Apr; 115(4):942-9. PubMed ID: 15805368
[TBL] [Abstract][Full Text] [Related]
54. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.
Peterson LR
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():181-4. PubMed ID: 18154544
[TBL] [Abstract][Full Text] [Related]
55. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
[TBL] [Abstract][Full Text] [Related]
56. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome.
Gudiol C; Calatayud L; Garcia-Vidal C; Lora-Tamayo J; Cisnal M; Duarte R; Arnan M; Marin M; Carratalà J; Gudiol F
J Antimicrob Chemother; 2010 Feb; 65(2):333-41. PubMed ID: 19959544
[TBL] [Abstract][Full Text] [Related]
57. Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2006 to 2010.
Lee YL; Chen YS; Toh HS; Huang CC; Liu YM; Ho CM; Lu PL; Ko WC; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Liu CE; Hsueh PR
Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S29-36. PubMed ID: 22749056
[TBL] [Abstract][Full Text] [Related]
58. Bloodstream infections caused by qnr-positive Enterobacteriaceae: clinical and microbiologic characteristics and outcomes.
Chong YP; Choi SH; Kim ES; Song EH; Lee EJ; Park KH; Cho OH; Kim SH; Lee SO; Kim MN; Jeong JY; Woo JH; Kim YS
Diagn Microbiol Infect Dis; 2010 May; 67(1):70-7. PubMed ID: 20227228
[TBL] [Abstract][Full Text] [Related]
59. Associated factors and clinical outcomes of bloodstream infection due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae during febrile neutropenia.
Ben-Chetrit E; Eldaim MA; Bar-Meir M; Dodin M; Katz DE
Int J Antimicrob Agents; 2019 Apr; 53(4):423-428. PubMed ID: 30572008
[TBL] [Abstract][Full Text] [Related]
60. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Chopra T; Marchaim D; Veltman J; Johnson P; Zhao JJ; Tansek R; Hatahet D; Chaudhry K; Pogue JM; Rahbar H; Chen TY; Truong T; Rodriguez V; Ellsworth J; Bernabela L; Bhargava A; Yousuf A; Alangaden G; Kaye KS
Antimicrob Agents Chemother; 2012 Jul; 56(7):3936-42. PubMed ID: 22547616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
